ALFA Finder| Revenue growth | 12.9% YoY for Q1 FY27 |
|---|---|
| Margins | EBITDA margin improved 250 bps YoY to 26.3%. |
| Demand visibility | Strong recovery in acute; double-digit growth in Mankind and BSV businesses. |
| Management confidence | High, citing disciplined execution and strengthening business fundamentals. |
Growth
Revenue reached INR 4,031 Cr (+12.9% YoY); EBITDA at INR 1,060 Cr (+24.7% YoY) with 26.3% margin.
Outlook
Focused on increasing chronic share (currently 39.6%) and integrating BSV specialty business for long-term sustainable growth.
Risks
Softness in consumer healthcare growth (4% YoY) due to discontinued cash and carry business base effect.
Last quarter's promises, checked
Delivered
- Guided 25-26% EBITDA margin → delivered 26.3% (= BEAT)
- Guided double-digit domestic growth → delivered 12.9% (= BEAT)
- Guided high-teens/20% exports growth → delivered 29% (= BEAT)
Partly delivered
- Guided 39% chronic share → delivered 39.6% (= PARTIAL)
Missed
- Guided double-digit consumer growth → delivered 4% (= MISS)
Investor Presentation filed with NSE, NSE: MANKIND. Summary written with AI assistance from the document.
Mankind Pharma Ltd: key numbers
- Share price
- ₹2,645.60
- Market cap
- ₹1,09,275 Cr
- Revenue (annual)
- ₹14,278 Cr
- Net profit (annual)
- ₹1,913 Cr
- P/E (TTM)
- 48.7×Sector 43.8×
- Promoter holding
- 72.62%-0.01% QoQ
- FII holding
- 9.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Mankind Pharma Ltd
All →Mankind Pharma Other Announcement
Mankind Pharma Limited received an ESG rating of 64.8 from SES ESG Research. This rating was independently assigned for FY26 based on publicly available information.
Mankind Pharma Credit Rating
CRISIL reaffirmed Mankind Pharma's AA+ rating on Rs.2,500 Crore of NCDs and withdrew ratings on Rs.2,500 Crore NCDs and Rs.1,500 Crore commercial paper. The rating action is dated October 29, 2026.
Mankind Pharma Earnings Call Transcript: Key Takeaways
Mankind Pharma delivered robust Q2 growth driven by chronic therapies and B-Spec specialty expansion. Strong operating leverage and margin expansion offset muted consumer health performance.
- Call
- Guides 20% growth
Mankind Pharma Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹4,338 Cr (+17.3% YoY), EBITDA ₹1,175 Cr (27.1% margin), PAT ₹716 Cr (+37.7%). Domestic ex-CH +15.9%, exports +32.7%, CH +1.2%.
Mankind Pharma Results Update
Mankind Pharma reported Q2 FY27 revenue of ₹4,338 Cr, up 17% YoY, and PAT of ₹716 Cr, up 38%. EBITDA margin improved 210 bps to 27.1%.
Mankind Pharma Acquisition
Mankind Pharma's board approved amalgamation of two wholly owned subsidiaries into the parent and a step-down subsidiary merger into MCPPL. Schemes require NCLT and shareholder approvals.